Casdin Capital

Casdin Capital, established in 2012 by Eli Casdin, is a New York-based venture capital firm with a focus on life sciences and healthcare. The firm specializes in investing in companies that are at the forefront of scientific and technological advancements in areas such as molecular medicine, biotechnology, genomics, and synthetic biology. Notable investments by Casdin Capital include high-impact companies like 23andMe, Adaptive Biotechnologies, Recursion Pharmaceuticals, and Ginkgo Bioworks. These investments highlight the firm’s commitment to transformative technologies in health care, gene editing, and diagnostic platforms. Casdin Capital's strategy revolves around funding companies that leverage data and precision-based therapies to revolutionize the healthcare industry. They focus on early-stage to late-stage investments, providing substantial financial support to help these companies scale and achieve significant milestones. The firm has managed to build a robust portfolio with 250 investments and 87 exits, demonstrating a strong track record of successful investments and strategic exits. Key team members include Eli Casdin as the Founder and Chief Investment Officer, Alexandria Fisk as Chief Operating Officer, and Lawrence Canzoneri as Chief Financial Officer. The team’s expertise and deep industry knowledge enable them to identify and support innovative startups effectively. Casdin Capital's approach combines strategic investments with deep sector expertise, positioning them as a leading player in the life sciences investment landscape, actively supporting companies that are poised to make groundbreaking advancements in health and biotechnology.